iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually
iSpecimen announced a major enhancement to its online biospecimen marketplace, expanding its searchable inventory of cancer samples across various tumor types. The company aims to streamline access to high-quality biospecimens for oncology research, supporting developments in therapies, diagnostics, and personalized medicine. Through new lead generation strategies and improved fulfillment timelines, iSpecimen projects potential orders worth $10,000,000 annually, expecting a 25% conversion rate leading to approximately 20% annual revenue growth.
iSpecimen ha annunciato un'importante miglioria al suo marketplace online di biospecimen, ampliando l'inventario ricercabile di campioni di tumore per diversi tipi di neoplasia. L'azienda mira a facilitare l'accesso a biospecimen di alta qualità per la ricerca oncologica, supportando lo sviluppo di terapie, diagnostica e medicina personalizzata. Attraverso nuove strategie di generazione di lead e tempi di evasione migliorati, iSpecimen prevede ordini potenziali per un valore di 10.000.000 di dollari all'anno, con un'aspettativa di un tasso di conversione del 25% che porterebbe a una crescita annuale dei ricavi di circa il 20%.
iSpecimen anunció una importante mejora en su mercado online de biospecímenes, ampliando su inventario buscable de muestras de cáncer en varios tipos de tumores. La compañía tiene como objetivo facilitar el acceso a biospecímenes de alta calidad para la investigación en oncología, apoyando el desarrollo de terapias, diagnósticos y medicina personalizada. A través de nuevas estrategias de generación de contactos y mejores plazos de cumplimiento, iSpecimen proyecta órdenes potenciales por un valor de $10,000,000 anuales, esperando una tasa de conversión del 25% que llevaría a un crecimiento anual de ingresos de aproximadamente el 20%.
iSpecimen은 온라인 바이오샘플 마켓플레이스의 주요 개선 사항을 발표하며 다양한 종양 유형의 암 샘플 검색 가능한 재고를 확장했습니다. 이 회사는 온콜로지 연구를 위한 고품질 바이오샘플 접근을 간소화하는 것을 목표로 하며, 치료법, 진단 및 개인 맞춤 의학의 발전을 지원합니다. 새로운 리드 생성 전략과 개선된 납품 일정을 통해 iSpecimen은 연간 10,000,000달러 가치의 잠재적 주문을 예상하고 있으며, 25%의 전환율을 기대하여 연간 수익이 약 20% 증가할 것으로 보고 있습니다.
iSpecimen a annoncé une amélioration majeure de son marché en ligne de biospécimens, élargissant son inventaire consultable d'échantillons de cancer à travers différents types de tumeurs. L'entreprise vise à simplifier l'accès à des biospécimens de haute qualité pour la recherche en oncologie, soutenant le développement de thérapies, de diagnostics et de médecine personnalisée. Grâce à de nouvelles stratégies de génération de leads et des délais d'éxécution améliorés, iSpecimen prévoit des commandes potentielles d'une valeur de 10 000 000 $ par an, avec une attente d'un taux de conversion de 25% entraînant une croissance annuelle des revenus d'environ 20%.
iSpecimen hat eine bedeutende Verbesserung seines Online-Marktplatzes für Biospecimens angekündigt, indem das durchsuchbare Inventar an Krebsmustern verschiedener Tumorarten erweitert wurde. Das Unternehmen hat das Ziel, den Zugang zu hochwertigen Biospecimens für die Onkologieforschung zu optimieren und Entwicklungen in den Bereichen Therapien, Diagnostik und personalisierte Medizin zu unterstützen. Durch neue Strategien zur Lead-Generierung und verbesserte Erfüllungszeiträume prognostiziert iSpecimen potenzielle Bestellungen im Wert von 10.000.000 US-Dollar pro Jahr, mit einer erwarteten Konversionsrate von 25%, die zu einem jährlichen Umsatzwachstum von etwa 20% führen könnte.
- Projected annual orders of $10,000,000 with expected 25% conversion rate
- Anticipated 20% annual revenue growth
- Enhanced operational efficiency through shortened sales and fulfillment timelines
- Expanded searchable inventory of cancer biospecimens
- None.
Insights
The expanded cancer biospecimen offering represents a significant business opportunity for iSpecimen, with potential annual orders of
A projected
The biospecimen market expansion into cancer research aligns with growing demand in oncology research and personalized medicine. By targeting high-value specimens across multiple cancer types, iSpecimen is positioning itself in a lucrative segment of the biospecimen market. The focus on operational efficiency through improved inventory searchability and faster fulfillment addresses key pain points in the research supply chain.
The implementation of multi-channel marketing strategies (email, organic search, SEM) indicates a sophisticated approach to market penetration. This comprehensive strategy could help capture market share in the competitive biospecimen space, though success will depend on maintaining specimen quality and provider network reliability.
WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments.
The expanded inventory includes highly sought-after cancer samples across a variety of tumor types, stages, and patient demographics, enabling researchers to access the specific samples they need efficiently and by cancer type, including colorectal, breast, lung, ovarian, pancreatic, brain, and more. By streamlining the acquisition of specific, high-quality biospecimens, iSpecimen is shortening sales and fulfillment timelines, increasing profitable revenue and supporting breakthroughs in cancer research, including studies focused on the development of new therapies, diagnostics, and personalized medicine approaches.
"Our mission has always been to connect researchers with the specimens they need to drive impactful advancements in healthcare," said Annette Arnold, Vice President of Sales and Business Development of iSpecimen. "With this expanded oncology biospecimen offering, we are empowering researchers around the world with access to critical resources that can fast-track their discoveries in cancer treatment and diagnostics to support life-saving treatments. We are also shortening lead times for order fulfillment which the Company expects to drive profitability for shareholders.”
In addition, the Company has rolled out new strategies and tactics for lead generation leveraging email marketing, organic search, and search engine marketing to increase inbound order volume. “We have expanded the pool of potential revenue by developing key capabilities to generate demand with our customers, both returning and new. We estimate there are
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Phil Carlson
iSpecimen@kcsa.com
FAQ
What is iSpecimen's (ISPC) projected annual order value for cancer biospecimens?
What is iSpecimen's (ISPC) expected annual revenue growth from the new cancer biospecimen offering?
What types of cancer samples does iSpecimen (ISPC) offer in their expanded inventory?
How is iSpecimen (ISPC) generating new leads for their biospecimen business?
